Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

Summary

This is a Phase 2/3, double-blind, randomized, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in adult participants with dermatomyositis (DM).

Timeline

Start

2021-11-19

Primary completion

2023-10-26

Completion

2024-05-08

Drugs

Indications